These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 36901738)

  • 1. Histone Deacetylases: Molecular Mechanisms and Therapeutic Implications for Muscular Dystrophies.
    Sandonà M; Cavioli G; Renzini A; Cedola A; Gigli G; Coletti D; McKinsey TA; Moresi V; Saccone V
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat.
    Consalvi S; Mozzetta C; Bettica P; Germani M; Fiorentini F; Del Bene F; Rocchetti M; Leoni F; Monzani V; Mascagni P; Puri PL; Saccone V
    Mol Med; 2013 May; 19(1):79-87. PubMed ID: 23552722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoplasmic HDAC4 regulates the membrane repair mechanism in Duchenne muscular dystrophy.
    Renzini A; Marroncelli N; Cavioli G; Di Francescantonio S; Forcina L; Lambridis A; Di Giorgio E; Valente S; Mai A; Brancolini C; Giampietri C; Magenta A; De Santa F; Adamo S; Coletti D; Moresi V
    J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1339-1359. PubMed ID: 35170869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HDAC inhibitors as pharmacological treatment for Duchenne muscular dystrophy: a discovery journey from bench to patients.
    Mozzetta C; Sartorelli V; Steinkuhler C; Puri PL
    Trends Mol Med; 2024 Mar; 30(3):278-294. PubMed ID: 38408879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pan HDAC inhibitor Givinostat improves muscle function and histological parameters in two Duchenne muscular dystrophy murine models expressing different haplotypes of the LTBP4 gene.
    Licandro SA; Crippa L; Pomarico R; Perego R; Fossati G; Leoni F; Steinkühler C
    Skelet Muscle; 2021 Jul; 11(1):19. PubMed ID: 34294164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting HDAC8 to ameliorate skeletal muscle differentiation in Duchenne muscular dystrophy.
    Spreafico M; Cafora M; Bragato C; Capitanio D; Marasca F; Bodega B; De Palma C; Mora M; Gelfi C; Marozzi A; Pistocchi A
    Pharmacol Res; 2021 Aug; 170():105750. PubMed ID: 34214631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitors: a potential epigenetic treatment for Duchenne muscular dystrophy.
    Consalvi S; Saccone V; Mozzetta C
    Epigenomics; 2014; 6(5):547-60. PubMed ID: 25431946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitors in the treatment of muscular dystrophies: epigenetic drugs for genetic diseases.
    Consalvi S; Saccone V; Giordani L; Minetti G; Mozzetta C; Puri PL
    Mol Med; 2011; 17(5-6):457-65. PubMed ID: 21308150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Givinostat as metabolic enhancer reverting mitochondrial biogenesis deficit in Duchenne Muscular Dystrophy.
    Giovarelli M; Zecchini S; Catarinella G; Moscheni C; Sartori P; Barbieri C; Roux-Biejat P; Napoli A; Vantaggiato C; Cervia D; Perrotta C; Clementi E; Latella L; De Palma C
    Pharmacol Res; 2021 Aug; 170():105751. PubMed ID: 34197911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy.
    Farr GH; Morris M; Gomez A; Pham T; Kilroy E; Parker EU; Said S; Henry C; Maves L
    Skelet Muscle; 2020 Oct; 10(1):29. PubMed ID: 33059738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HDAC-regulated myomiRs control BAF60 variant exchange and direct the functional phenotype of fibro-adipogenic progenitors in dystrophic muscles.
    Saccone V; Consalvi S; Giordani L; Mozzetta C; Barozzi I; Sandoná M; Ryan T; Rojas-Muñoz A; Madaro L; Fasanaro P; Borsellino G; De Bardi M; Frigè G; Termanini A; Sun X; Rossant J; Bruneau BG; Mercola M; Minucci S; Puri PL
    Genes Dev; 2014 Apr; 28(8):841-57. PubMed ID: 24682306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment.
    Colussi C; Mozzetta C; Gurtner A; Illi B; Rosati J; Straino S; Ragone G; Pescatori M; Zaccagnini G; Antonini A; Minetti G; Martelli F; Piaggio G; Gallinari P; Steinkuhler C; Clementi E; Dell'Aversana C; Altucci L; Mai A; Capogrossi MC; Puri PL; Gaetano C
    Proc Natl Acad Sci U S A; 2008 Dec; 105(49):19183-7. PubMed ID: 19047631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histological effects of givinostat in boys with Duchenne muscular dystrophy.
    Bettica P; Petrini S; D'Oria V; D'Amico A; Catteruccia M; Pane M; Sivo S; Magri F; Brajkovic S; Messina S; Vita GL; Gatti B; Moggio M; Puri PL; Rocchetti M; De Nicolao G; Vita G; Comi GP; Bertini E; Mercuri E
    Neuromuscul Disord; 2016 Oct; 26(10):643-649. PubMed ID: 27566866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of epigenetic resistance to HDAC inhibitors in dystrophic fibro-adipogenic progenitors.
    Consalvi S; Tucciarone L; Macrì E; De Bardi M; Picozza M; Salvatori I; Renzini A; Valente S; Mai A; Moresi V; Puri PL
    EMBO Rep; 2022 Jun; 23(6):e54721. PubMed ID: 35383427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of YSR734: A Covalent HDAC Inhibitor with Cellular Activity in Acute Myeloid Leukemia and Duchenne Muscular Dystrophy.
    Raouf YS; Sedighi A; Geletu M; Frere GA; Allan RG; Nawar N; de Araujo ED; Gunning PT
    J Med Chem; 2023 Dec; 66(24):16658-16679. PubMed ID: 38060537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDAC inhibitors tune miRNAs in extracellular vesicles of dystrophic muscle-resident mesenchymal cells.
    Sandonà M; Consalvi S; Tucciarone L; De Bardi M; Scimeca M; Angelini DF; Buffa V; D'Amico A; Bertini ES; Cazzaniga S; Bettica P; Bouché M; Bongiovanni A; Puri PL; Saccone V
    EMBO Rep; 2020 Sep; 21(9):e50863. PubMed ID: 32754983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-histone substrates of histone deacetylases as potential therapeutic targets in epilepsy.
    Kumar S; Attrish D; Srivastava A; Banerjee J; Tripathi M; Chandra PS; Dixit AB
    Expert Opin Ther Targets; 2021 Jan; 25(1):75-85. PubMed ID: 33275850
    [No Abstract]   [Full Text] [Related]  

  • 19. Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.
    Zaikos TD; Painter MM; Sebastian Kettinger NT; Terry VH; Collins KL
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29298886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanism of sphingosine-1-phosphate action in Duchenne muscular dystrophy.
    Nguyen-Tran DH; Hait NC; Sperber H; Qi J; Fischer K; Ieronimakis N; Pantoja M; Hays A; Allegood J; Reyes M; Spiegel S; Ruohola-Baker H
    Dis Model Mech; 2014 Jan; 7(1):41-54. PubMed ID: 24077965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.